Skip to main content
. Author manuscript; available in PMC: 2018 Feb 26.
Published in final edited form as: Aging Clin Exp Res. 2017 Nov 24;30(2):111–117. doi: 10.1007/s40520-017-0861-1

Table 1.

Symptom outcomes for patented crystalline glucosamine sulfate (pCGS) formulation after 6 months to 3 years of treatment for knee osteoarthritis

Outcome Fixed-model effect size (95% CI)†
WOMAC scale
   Total 0.33 (0.17-0.49)
   Pain 0.27 (0.12-0.43)
   Function 0.33 (0.17-0.48)
Lequesne index‡ 0.38 (0.19-0.57)
†

Pooled effect size: Estimates and 95% CIs from fixed-model meta-analysis method using the pooled standard deviation in each study/outcome [26–28];

‡

Not assessed in 1 study[27]. Heterogeneity, I2 = 0.00. Table adapted from Reginster 2007 [23]